Financial Performance - Aadi Bioscience reported a quarterly loss of 0.60 per share a year ago [1] - The company posted revenues of 5.96 million in the same quarter last year [2] - The current consensus EPS estimate for the upcoming quarter is -6.77 million, and for the current fiscal year, it is -24.86 million [7] Market Performance - Aadi Bioscience shares have declined approximately 1.5% since the beginning of the year, contrasting with the S&P 500's gain of 21.2% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Aadi Bioscience belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]
Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue Estimates